New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 29, 2014
07:41 EDTBIIBBiogen to present two-year data from Plegridy Phase 3 study at AAN meeting
Biogen Idec announced two-year data from its Phase 3 ADVANCE clinical trial for PLEGRIDY in people with relapsing forms of multiple sclerosis. These data, which will be presented at the 66th American Academy of Neurology annual meeting, indicate PLEGRIDY dosed once every two weeks demonstrated favorable results on relapse rates, magnetic resonance imaging findings and disease progression. Over two years, the safety profile of PLEGRIDY was consistent with other multiple sclerosis interferon therapies. “The two-year data from ADVANCE further establish the efficacy and safety profile of PLEGRIDY demonstrated in the first year of the pivotal trial,” said Gilmore O’Neill, vice president, Global Neurology Clinical Development at Biogen Idec. “If approved, we believe that PLEGRIDY dosed once every two weeks will provide MS patients with one of the most significant developments in the interferon class in over a decade.” ADVANCE was a two-year, Phase 3, placebo-controlled study that evaluated the efficacy and safety of PLEGRIDY administered subcutaneously. The analysis for all primary and secondary efficacy endpoints occurred at the end of year one. After the first year, patients on placebo received PLEGRIDY for the duration of the study.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
08:01 EDTBIIBPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 9, 2014
12:22 EDTBIIBPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use